See More. Know More. Treat Smarter.

CLINICAL CONFIDENCE FROM PRECISION TARGETING


ASTRAL's integrated OCT generates 120 cross-sectional radial views of the eye's Anterior Chamber, delivering a comprehensive view of the iridocorneal angle. Simply navigate around the eye and ASTRAL Intelligence displays the corresponding OCT for each potential treatment location.

When seeing is believing, ASTRAL lets you ...



TARGET THE TRABECULAR MESHWORK

True anatomical targeting in the stacked images from the **four cardinal planes.**




TECHNICAL SPECIFICATIONS

SLT LASER	
Type	Q-Switched frequency doubled Nd:YAG
Wavelength	532 nm
Energy	Adjustable 1.1 - 1.9 mJ
Burst Mode	Single pulse only
Spot size	400 µm
Beam Divergence	≤0.031 radians
Maximum Repetition Rate	50 Hz
Pulse width/duration	3±20% ns
Nominal Ocular Hazard Distance (NOHD)	40.8 m
Cooling	air cooled
Maximum Permissible Exposure (MPE) at the cornea (J/m2) for NOHD calculations using an assumed exposure duration between 1 ns and 100 ns:	$2x10^{-3}$

OCT MODULE	
Line Sensor Type	InGaAs
Number of pixels	1024
Pixel height	250 µm
Pixel pitch	12 µm
Maximum line rate	40 kHz
Digital output format	16 bit GigE

COMMON FEATURES SPECIFICATIONS	
Weight	38 kg
Dimensions (HxWxD)	530 x 680 x 850 mm
Operating conditions	+15 °C to +35 °C / 35% to 85% relative humidity non-condensing
Storage and transport conditions	–10 °C to +55 °C / 10% to 85% relative humidity non-condensing
Power Supply	100–240 VAC single phase, 50/60 Hz, 300 W, 4A 250V, 5 × 20 mm High Breaking Capacity
Screen	Color Touch Screen, Panel size 15.6", HD Panel resolution 1920x1080. Mounted on an articulated arm rotatable through 270 degrees around the platform.
Computer	PC Tablet WIN 11 IOT
Network connectivity	LAN connection, DICOM compatible
Standard Accessories	Safety glasses, laser safety sign, dust cover
Optional Accessories	Motorised Height Adjustable Table

ASTRAL



Specifications are subject to change without notice. Non contractual pictures. "2026. ASTRAL" is a trademark of Ellex Medical Pty Ltd, Ellex Medical Pty Ltd, member of Lumibird Medical Division. All rights reserved.

Bibliography

1- For publicly available study information and summary results, please refer to ClinicalTrials.gov.

Reference: ClinicalTrials.gov. Identifier: NCT06833060. Exploratory Clinical Study of a Laser-OCT Integrated System With Eye Tracking to Treat Glaucoma and OHT With Transscleral Selective Laser Trabeculoplasty Technology: A Pilot Study (TSLT-001-2023). Available at: https://clinicaltrials.gov/study/NCT06833060

2- Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. LiGHT trial: 6-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2022;16:S0161-6420(22)00732-1

84A8345EN-B - ASTRAL - XL_ASTRAL_BCK_AN_260828



CE 2797

Manufacturer
Ellex Medical Pty Ltd
3-4 Second Avenue
Mawson Lakes, SA 5095 AUSTRALIA
Tel: +61 (0)8 7074 8200
ISO 13485 : 2016

Headquarters
Lumibird Medical
1, rue du Bois Joli - CS40015
63808 Cournon d'Auvergne - FRANCE
Tel: +33 (0)4 73 745 745

ELLEX *A brand of* LUMIBIRD® MEDICAL

www.lumibirdmedical.com

ASTRAL®

SLT LASER
OCT **VISUALIZATION** SYSTEM



ellex BY LUMIBIRD MEDICAL

ASTRAL®

SLT Laser - OCT Visualization System

EFFECTIVE, SAFE, PRECISE, CONFLUENT SLT



A NEW ERA IN SLT TREATMENT

Leveraging 40 years of laser expertise, Ellex, a brand of Lumibird Medical introduces **ASTRAL®**, an innovative SLT platform featuring:

- **OCT visualization system** for accurate trabecular meshwork targeting
- **Lens-free transscleral delivery** for a streamlined treatment experience
- Comparable outcomes to traditional SLT in **under three seconds**[1]

OPTIMIZED WORKFLOW AND PATIENT EXPERIENCE

ASTRAL improves your clinic workflow by significantly reducing preparation and post-treatment time while enhancing the patient experience through its gentle, non-contact application.





ASTRAL's 270-degree articulated monitor lets clinicians sit comfortably beside the patient, providing reassurance and easy eyelid manipulation. The flexible design supports a natural posture, while the forward-angled headrest enhances patient fixation and stability for precise treatment.



ASTRAL® INTELLIGENT SOFTWARE

- Streamlines patient setup and treatment workflow.
- Align. Focus. Acquire. Assisting clinicians in targeting and treating the trabecular meshwork.
- Set configurable exclusion zones as required.





SLT FOR GLAUCOMA TREATMENT

SLT is now recommended (LiGHT trial) as a first-line treatment by AAO, EGS, APGS and WGA.

- **69,8%** OF SLT PATIENTS REACHED TARGET IOP AND WERE DROP-FREE
- VISUAL FIELD IN SLT PATIENTS SHOWED LESS DAMAGE THAN EYE DROP USERS
- MORE COST EFFECTIVE THAN DROPS
- PATIENT COMPLIANCE: SLT: 100% - DROPS: 20-50%

LINK TO THE STUDY

CONCLUSION: SLT is a safe treatment for OAG and OHT, providing better long-term disease control than initial drop therapy, with reduced need for incisional glaucoma and cataract surgery over 6 years[2].

15 sec

PATIENT PROCEDURE ENGAGEMENT TIME

Locate and focus ~7 seconds

Acquire OCT ~5 seconds

Treat < 3 seconds

PATIENTS RETURN TO DAILY ACTIVITIES WITHIN MINUTES.

NO CONTACT GEL = NO SUSTAINED BLURRED VISION

TREAT GLAUCOMA IN MORE PATIENTS PER HOUR WITH LOWER COST PER TREATMENT